Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 214 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Cerebral MR Imaging in Uninfected Children Born to HIV-Seropositive Mothers and Perinatally Exposed to Zidovudine
AJNR 26:695-701,687, Tardieu,M.,et al, 2005

Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022

Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021

Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020

Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020

Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020

Toxoplasmosis in HIV-Infected Patients
www.UptoDate.com, May, Gandhi, R.T., 2019

A 56-year-old woman with acute vertigo and diplopia
Neurol 90:748-752, Sharma, R.,et al, 2018

Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017

Intracranial Meningeal Enhancement Characterization
Rev Colomb Radiol 28:4709-4716, Mera, J.L.C.,et al, 2017

Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017

Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016

Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015

A 35-Year-Old Man with 2 Episodes of Meningoencephalitis Associated with Flu-Like Illness
Neurol 84:e60-e64, Lewis, S.L., 2015

Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015

The Importance of Lesbian, Gay, Bisexual and Transgender Health in Neurology
JAMA Neurol 72:855, Rosendale, N. & Josephson, S.A., 2015

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Fungal Infections Associated with Contaminated Methylprednisolone Injections - Preliminary Report
NEJM 368:2495-2509, Kauffman, C.,et al, 2013

Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013

Lamotrigine and Aseptic Meningitis
Neurol 78:921-927, Simms,K.M.,et al, 2012

Acute Symptomatic Seizures
The Neurologist 18:109-119, Beleza,P., 2012

Preexposure Prophylaxis for HIV - Where Do We Go from Here?
NEJM 367:459-461,462, Cohen, M.S. & Baden, L.R., 2012

Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012

Fatal Varicella-Zoster Virus Vasculopathy Associated with Adalimumab Therapy
Arch Neurol 69:1193-1196, Baek, W.,et al, 2012

Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012

Primary Varicella Zoster Infection Associated With Fingolimod Treatment
Neurol 76:1023-1024, Uccelli,A.,et al, 2011

Prevention of HIV-1 Infection with Early Antiretroviral Therapy
NEJM 365:493-505,561, Cohen, M.S.,et al, 2011

Lamotrigine: An Unusual Etiology for Aseptic Meningitis
Neurologist 16:35-36, Lam,G.,et al, 2010

Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009

Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009

Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009

Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008

Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008

Reversible Posterior Leukoencephalopathy Syndrome in 2 HIV-Infected Patients Receiving Antiretroviral Therapy
CID 49:e19-e22, Ridolfo, A.L.,et al, 2008

Facial Weakness in a Haemodialysis Patient
Lancet 369:714, Papadakis,M.,et al, 2007

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007

Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006

Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006

Recurrent Ibuprofen-Induced Aseptic Meningitis: Evidence Against an Antigen-Specific Immune Response
Neurol 67:539-540, Periard,D.,et al, 2006

Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006

Spectrum and Prognosis of Neurologic Complications After Hematopoietic Transplantation
Neurol 67:1990-1997, Denier,C.,et al, 2006

Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005

FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005

Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005



Showing articles 0 to 50 of 214 Next >>